AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-8. (cancelled)

9. (withdrawn and currently amended) A method for treating urinary tract infection, comprising administering an effective amount of at least one therapeutic agent which is an alpha-aminoamide compound of formula (I),



(I)



---

wherein:

R is a furyl, thienyl, or pyridyl ring or a phenyl ring, optionally substituted by one or two substituents

independently selected from halogen, hydroxy, cyano, ~~C1-C6~~ C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl; [[*]]

~~Ri~~ R_1 is hydrogen or C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

R_2 and R_3 are independently selected from hydrogen; C_1-C_4 alkyl, optionally substituted by hydroxy or phenyl, phenyl[[,]] in which the phenyl rings being optionally substituted by one or two substituents independently selected from C_1-C_6 alkyl, halogen, hydroxy, ~~C1-C6~~ C_1-C_6 alkoxy or trifluoromethyl; or R_2 and R_3 taken with the carbon atom which they are linked to, form a C_3-C_6 cycloalkyl ring; [[#]]

~~R4, R5~~ R_4 and R_5 are[[,]] independently[[,]] hydrogen, C_1-C_6 alkyl or C_3-C_7 cycloalkyl; or R_4 and R_5, taken together with the nitrogen atom they are linked to, form a 5-7 atom saturated heterocyclic ring;

X is ~~CH2~~ CH_2, O, S; and

~~dz Z are hydrogen or taken together form a 5 7 saturated or unsaturated carbocycle or a heterocycle~~ Y and Z taken together form a dihydrobenzofuran, and/or;

~~or isomers~~ stereoisomers, mixtures, and pharmaceutically acceptable salts thereof.

10. (withdrawn and currently amended) The method according to claim 9, wherein the compound is selected from:

2-[(3-Benzyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-propanamide; 2-[(3-Benzyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-N-methyl-propanamide; 2-{3-[2-(2-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; ~~

~~ 2-{3-[2-(2-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N-methyl-propanamide; 2-{3-[2-(3-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; ~~

~~ 2-3-[2-(3-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N-methyl-propanamide; 2-[(3-Phenethyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-propanamide; 2-[(3-Phenethyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-N-methyl-propanamide; 2-3-[2-(2-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; 2-3-[2-(2-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl)-amino)-N-methyl-propanamide; 2-3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; ~~

~~ 2-{3-[2-(3-Chloro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; ~~

~~ and 2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N-methyl-propanamide~~;~~

~~2-[(3-Phenethyl-2,3-dihydro-benzopyran-6-ylmethyl)-amino]-propanamide; 2-[(4-Phenethyl-2,3-dihydro-benzoxepin-7-ylmethyl)-amino]-propanamide; 2-[(3-Benzyl-2,3-dihydro-~~

~~benzothiophen-5-ylmethyl)-amino]-propanamide; 2-{3-[2-(2-Fluoro-benzyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(3-Fluoro-benzyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide; 2-{(3-Phenethyl-2,3-dihydro-benzothiophen-5-ylmethyl)-amino]-propanamide; 2-{3-[2-(2-Fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl)-amino)-propanamide; and 2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-N-methyl-propanamide~~.

11. (withdrawn) The method according to claim 9, wherein the compound is selected from: 2-(4-Phenethyl-benzylamino)-propanamide; 2-(4-Benzyloxybenzylamino)-propanamide; 2-(3-Benzyloxybenzylamino)-propanamide; 2-(4-Benzylthiobenzylamino)-propanamide; 2-(4-Benzyloxy-benzylamino)-3-N,N-dimethyl-butanamide; 2-[4-(2-Methoxybenzyloxy)-benzylamino]-propanamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-propanamide; 2-[3-(2-Fluorobenzyloxy)-benzylamino]-propanamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-propanamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-2-methyl-propanamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-N-methyl-propanamide; 2-[3-(3-Fluorobenzyloxy)-benzylamino]-propanamide; 2-[4-(3-

Fluorobenzyloxy)-benzylamino]-propanamide; 2-[4-(3-Methoxybenzyloxy)-benzylamino]-propanamide; 2-[4-(3-Cyanobenzyloxy)-benzylamino]-propanamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-propanamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-2-methyl-propanamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-N-methyl-propanamide; 2-[4-(4-Fluorobenzyloxy)-benzylamino]-propanamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-2-methyl-propanamide; 2-[4-(2-Chlorobenzyloxy)-benzylamino]-propanamide; 2-[4-(3-Chlorobenzyloxy)-benzylamino]-propanamide; 2-(4-Benzyloxybenzylamino)-3-hydroxy-propanamide;2-[4-(2-Fluorobenzyloxy)-benzylamino]-3-hydroxy-propanamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-3-hydroxy-propanamide; 2-(4-Benzyloxybenzylamino)-3-hydroxy-N-methyl-propanamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-3-hydroxy-N-methyl-propanamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-3-hydroxy-N-methyl-propanamide; 2-[4-(2-Chlorobenzyloxy)-benzylamino]-3-hydroxy-N-methyl-propanamide; 2-[4-(3-Cyanobenzyloxy)-benzylamino]-3-hydroxy-N-methyl-propanamide; 2-[4-(3-Cyanobenzyloxy)-benzylamino]-2-methyl-3-hydroxy-N-methyl-propanamide; 2-[4-(3-Chlorobenzyloxy)-phenylethylamino]-propanamide; 2-{4-[2-(3-Fluorophenyl)-ethyloxy]benzylamino}-propanamide; 2-{4-[2-(3-Fluorophenyl)-ethyl] benzylamino}-propanamide; 2-[N-(4-Benzyloxybenzyl)-N-methylamino]-propanamide; 2-4-[(3-

Chlorobenzyloxy)-phenylethyl]-amino}-propanamide; 2-[4-Benzylthiobenzylamino]-propanamide; 2-[4-(2-Fluorobenzylthio)-benzylamino]-propanamide; 2-[4-(3-Fluorobenzylthio)-benzylamino]-propanamide; 2-[4-(3-Phenylpropyloxy)-benzylamino]-propanamide; 2-[4-(4-Phenylbutyloxy)-benzylamino]-propanamide; 2-[4-(5-Phenylpentyloxy)-benzylamino]-propanamide; 2-(4-Benzyloxybenzylamino)-3-phenyl-N-methyl-propanamide; 2-(4-Benzyloxybenzylamino)-3-hydroxy-N-methyl-butanamide; 2-(4-Benzyloxybenzylamino)-3-methyl-N-methyl-butanamide; 2-(4-Benzyloxybenzylamino)-2-phenyl-acetamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-2-phenyl-acetamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-2-phenyl-acetamide; 2-[4-(2-Fluorobenzyloxy)-benzyl-N-methylamino]-2-phenyl-acetamide; 2-[4-(3-Fluorobenzyloxy)-benzyl-N-methylamino]-2-phenyl-acetamide; 2-[4-(3-Chlorobenzyloxy)-benzylamino]-2-phenyl-acetamide; 2-[4-(2-Fluorobenzyloxy) benzylamino]-2-(2-fluorophenyl)-acetamide; 2-[4-(2-Fluorobenzyloxy)-benzylamino]-2-(3-fluorophenyl)-acetamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-2-(2-fluorophenyl)-acetamide; 2-[4-(3-Fluorobenzyloxy)-benzylamino]-2-(3-fluorophenyl)-acetamide; 2-[4-(3-Chlorobenzyloxy)-benzylamino]-2-(3-fluorophenyl)-acetamide; and 2-(4-(2-Thienyloxy)-benzylamino)-propanamide.

12. (withdrawn) The method of claim 9, wherein said lower urinary tract disorders are overactive bladder (OAB), prostatitis and prostadynia, interstitial cystitis, benign prostatic hyperplasia and urinary incontinence as the consequence of the above pathologies.

13. (withdrawn and currently amended) The method of claim 9, wherein the ~~a-aminoamides~~ α-aminoamides are (S)-(+)-2-[3-(2-fluorobenzyloxy)-benzylamino]-propanamide; (S)-(+)-2-[4-(2-~~

~~fluorobenzyloxy)-benzylamino]-propanamide, (S)-(+)-2-[4-(2-fluorobenzyloxy)-~~

~~benzylamino]-N-methyl-propanamide, (S)-(+)-2-[3-(3-fluorobenzyloxy)-~~

~~benzylamino]-propanamide, (S)-(+)-2-[4-(3-fluorobenzyloxy)-benzylamino]-propanamide, (R)-2-(4-benzyloxybenzylamino)-3-phenyl-N-methyl-propanamide; (2R,3S)-2-(4-Benzyloxybenzylamino)-3-hydroxy-N-methyl-butanamide; (S)-(+)-2-[4-(3-fluorobenzyloxy)-benzylamino]-N-methyl-propanamide, (S)-(+)-2-(4-phenethyl-benzylamino)-propanamide, (R)-(-)-2-(4-benzyloxy-benzylamino)-3-N,N-dimethyl-butanamide, (S)-(+)-2-(4-benzylthiobenzylamino)-propanamide, and 2-[(3-phenethyl-2, 3-dihydro-benzofuran-5-ylmethyl)-amino]-N-methyl-propanamide and (2R/3'S,R)-2-[(3-phenethyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-N-methyl-propanamide, 2-{3-[2-

(2-fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide, 2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide, (2R/3'S,R)-2-{3-[2-(2-fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide, (2R/3'S,R)-2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide.

14. (currently amended) An α-aminoamide compound represented by the following formula (I):





---

wherein:

R is a furyl, thienyl, pyridyl ring or a phenyl ring, optionally substituted by one or two substituents independently selected from halogen, hydroxy, cyano, C_1-C_6 alkyl, C_1-C_6 alkoxy or trifluoromethyl;

R_1 is hydrogen or C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

R_2 and R_3 are independently selected from hydrogen, C_1-C_4 alkyl optionally substituted by hydroxy or phenyl, phenyl in which the phenyl rings being optionally substituted by one or two substituents independently selected from C_1-C_6 alkyl, halogen, hydroxy, C_1-C_6 alkoxy or trifluoromethyl; or R_2 and R_3, taken with the carbon atom which they are linked to, form a C_3-C_6 cycloalkyl ring;

R_4 and R_5 are independently hydrogen, C_1-C_6 alkyl or C_3-C_7 cycloalkyl; or R_4 and R_5, taken together with the nitrogen atom they are linked to, form a 5-7 atom saturated heterocyclic ring;

X is CH_2, O, or S; and

Y and Z taken together form a dihydrobenzofuran, ~~a dihydrobenzothiophen, a dihydrobenzo (thio) pyran, or a tetrahydrobenz (thio) oxepin heterocycle~~ and/or ~~isomers~~ stereoisomers, mixtures, and pharmaceutically acceptable salts thereof.

15. (currently amended) The compound according to claim 14, wherein said compound is selected from the group consisting of:

2-[(3-Benzyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-propanamide; 2-[(3-Benzyl-2,3-dihydro-benzofuran-5-

ylmethyl)-amino]-N-methyl-propanamide; 2-{3-[2-(2-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(2-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N-methyl-propanamide; 2-{3-[2-(3-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(3-Fluoro-benzyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N- methyl-propanamide; 2-[(3-Phenethyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-propanamide; 2-[(3-Phenethyl-2,3-dihydro-benzofuran-5-ylmethyl)-amino]-N-methyl-propanamide; 2-{3-[2-(2-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(2-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N-methyl-propanamide; 2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(3-Chloro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-propanamide; and 2-{3-[2-(3-Fluoro-phenethyl)]-2,3-dihydro-benzofuran-5-ylmethyl}-amino)-N-methyl-propanamide; ~~2-[(3-Phenethyl-2,3-dihydro-benzopyran-6-ylmethyl)-amino]-propanamide; 2-[(4-Phenethyl-2,3-dihydro-benzoxepin-7-ylmethyl)-amino]-propanamide; 2-[(3-Benzyl-2,3-dihydro-benzothiophen-5-ylmethyl)-amino]-propanamide; 2-{3-[2-(2-Fluoro-benzyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide; 2-{3-[2-(3-Fluoro-benzyl)]-2,3-dihydro-benzothiophen-5-ylmethyl}-amino)-propanamide; 2-[(3-Phenethyl-~~

~~2,3 dihydro-benzothiophen-5-ylmethyl) amino] propanamide; 2-{3-[2-(2-Fluoro-phenethyl)] 2,3 dihydro-benzothiophen-5-ylmethyl) amino) propanamide; 2-{3-[2-(3-Fluoro-phenethyl)] 2,3 dihydro-benzothiophen-5-ylmethyl) amino) propanamide; 2-{3-[2-(3-Fluoro-phenethyl)] 2,3 dihydro-benzothiophen-5-ylmethyl) amino) N-methyl-propanamide;~~ and

~~isomers~~ stereoisomers, mixtures, or pharmaceutically acceptable salts thereof.

16. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and, as an active agent, an effective amount of the α-aminoamide compound according to claim 14.